Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation develops and markets therapies for rare cardiopulmonary and related diseases, with a pulmonary arterial hypertension franchise built around treprostinil products such as Tyvaso DPI, Tyvaso Inhalation Solution, Remodulin and Orenitram. News commonly covers product sales, quarterly results, clinical data for pulmonary hypertension, idiopathic pulmonary fibrosis and interstitial lung disease, and updates on ralinepag and the TETON program.
The company also reports developments in manufactured-organ and transplant-support technologies, including EVLP, xenotransplantation, and Miromatrix Medical programs such as miroliverELAP and mirokidney. Governance updates, board composition, share repurchase activity and its status as a public benefit corporation are recurring corporate themes.
United Therapeutics (Nasdaq: UTHR) has announced that it will release its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. A press release detailing the quarterly results will be issued at approximately 6:30 a.m. Eastern Time. The company will host a public webcast at 9:00 a.m. Eastern Time on the same day, accessible via their website. A rebroadcast of the webcast will be available for one year.
United Therapeutics is a publicly-traded biotech company that has taken the form of a public benefit (PBC). Their mission focuses on innovating for unmet medical needs and developing novel pharmaceutical therapies and technologies to expand the availability of transplantable organs.
United Therapeutics (Nasdaq: UTHR) announced the full enrollment of the TETON 2 study, evaluating Tyvaso® (treprostinil) inhalation solution for idiopathic pulmonary fibrosis (IPF). The study enrolled 597 patients outside the U.S. and Canada and is part of a global program assessing inhaled treprostinil in IPF and progressive pulmonary fibrosis (PPF). Top-line data is expected in the second half of 2025. The TETON program is inspired by favorable outcomes from the INCREASE study, which showed significant improvements in forced vital capacity (FVC) for IPF patients using nebulized Tyvaso. United Therapeutics aims to use these studies to seek FDA approval for Tyvaso DPI to treat IPF and PPF.
United Therapeutics (Nasdaq: UTHR) has elected Jan Malcolm, former Minnesota Commissioner of Health, to its Board of Directors. She was elected by shareholders during the annual meeting on June 26, 2024. Malcolm has a distinguished career in health policy, public health, and healthcare finance, highlighted by her leadership during the COVID-19 pandemic in Minnesota and her recognition by the American Medical Association with the AMA Award for Outstanding Government Service. Her experience includes roles at Allina Health and Courage Center. Malcolm will contribute to United Therapeutics' mission to address unmet medical needs, particularly in the area of end-stage organ diseases.
United Therapeutics (Nasdaq: UTHR) will present at the Goldman Sachs 45th Annual Global Healthcare Conference. Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company's operations during a fireside chat session. This session is scheduled for Wednesday, June 12, 2024, from 4:00 p.m. to 4:35 p.m. Eastern Daylight Time in Miami Beach, Florida. The session will be accessible via a live webcast on United Therapeutics' website and will be archived for 90 days post-event. United Therapeutics, a public benefit , focuses on developing novel pharmaceutical therapies and technologies to expand the availability of transplantable organs.
United Therapeutics reported strong financial results for the first quarter of 2024, with total revenues growing by 34 percent year-over-year to $677.7 million. The company's net income also increased by 27 percent, demonstrating its solid commercial foundation and growth potential. Key highlights include the implementation of a $1 billion accelerated share repurchase program, showcasing confidence in the company's future prospects.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.